I have been wondering about the point you are making about day traders. The volume is so low that I believe day traders perhaps are not likely to play it for pennies when there are hundreds of other stocks where they can make better gain. Perhaps, it's MM and some dedicated Geron haters who want to get even!!
Geron shares have returned to its original trend: Go down 3 to 4 imes more than the market when the market is down but doesn't quite do vice versa! Any guesses as to why?!!!!
dan, with the advent of computerized trading and govt policy of allowing banks to do securities trading business, easy-money hunters are in full force at Wall Street. The days of primarily retail trading and company-fundamentals based investment are just a thing of the past. Just understand how these modern market-crooks play and follow to seek your goal.
Institutional players are well-versed in traders' techniques and psychology. Some of these may have direct link to MM who can manipulate share price. When a company like ACTC have product(s)under testing that's potetially lucrative and the company is a potential target of larger companies, these instituirtutional crooks manipulate trading of of shares of such a company with cooperation of the MM to their advantage. This is what is I believe going on currently with ACTC share trading. If you're smart, just grab more on chart-indicated lows.
Did idiots generally posting on this notice what my posts above stated? Some bashed Rabin, some show sre-price collapse and some calcaulated share price to go down to 4 cents!! All baloney, isn't it?
It's simply overreaction being fattened and taken advantage by the MM and certain institutional players to grab the shares at the lowest possible price. You will be a fool not add more, if you can, when the price dips below 0.06
Looking at no response in two hours to your post which all idiots should read, I gather that it's worthless to post anyything sensible on this board. Such an effort is just a waste and like talking to deaf ears!!
Look at the chart and you will see that traders and MM are just playing games. Generally, a MM is smareter than traders and he maipulates monkey traders, both helping liquidity of the market. There is no fundamental change in the company or its operation. I would say this is an ooportunity for investors to add more. ,
and nothing else is causing the share-price drop, taking advantage of the latest-quarter results announcement and using that as an excuse. Traders and MM both want to make money!! Long holders should just stay put and let monkeys hop out and then in!!..
I think, the Mayo work ads a lot of credibility and energy into this. If anyone needs to be called the savior of thi company/stock at this point, it's neither Okarma (for his stem-cell deal through BioTime) nor Huh or even Scarlett, it's that Mayo guy Tifferi. If he did not take up Imetelstat boldly, like he did, to try on hopeless MF patients, I wonder if Scarlett would have sounded as optimistic as he did in yesterday's CC.
Black, just a month or so back you stated that you will stick with what you had then!! I think you have made a hasty decision - just my belief.
Looks like three posters find my above post agreeable, and none find it disagreeable! I invite more posters to go through the CC transcript again caefully and cast their opinion. Thanks.
His responses to the Piper Jeffrey and Stfel Nicolaus guys' questions clearly show Scarlett's personal confidence in the success of Imtelstat for the myeloid application, beating all competition. To quote, "I think this is quite a different product. It is a product that is given by infusion. Most of the other -- for example, JAK inhibitors are oral agents. As we've sort of harped on, we think that there is at least the potential for disease modification, meaningful disease modification. I think the history of most of this JAK inhibitor is not to throw cold water on them. If I had MF, I want to be taking one today. But nevertheless, they haven't shown themselves to be very effective in addressing the underlying malignant clone and malignant disease. And so I think it's quite -- this is quite a unique drug, and so we'll have to see the -- I think we'll have to all see the full profile, and then I think it will become fairly evident where it sits in the competitive landscape."
Later, while responding to the SN guy, his confidence in Imetelstat achieving PR (partial remission) or even CR (complete remission) of the disease and bringing bone marrow to its normal condition (which no curent drug can attain) is very evident. This kind of confidence was never expressed by him in any of the past CCs.
With Dr. Tefferi's work, and thus Mayo's stamp of approval, Geron's Imetelstat success is bound to be a reality waiting to reward shareholders.
I think he has rigthly focussed on Imetelstat in preference to the hESC activity, especilly looking at the financial condition of the company. I have to change my own pessimistic opinion about him and certainly be more optimistic about the company's success now.
The company situation has been getting better compared to that last year; but, the monkeys (I mean including those in Wall Street) dumped Geron shares lately and now they are jumping in again! It's fun watching them hop out and in!!! No matter what the share price indicates, the blast stage MF trial will be taken up and th trial for MF will be moving into Ph. III And, Imtelestat would finally be a part of clinical cancer treatment within a few years for several myeloid and perhaps other cancers. That seems to be closer to reality. However, all have forgotten what is going on with the BioTime deal. Is it going to be finalized now in September or not? The monkeys, of course, are not concerned about it; they want to dwell only in hot news now.
Isn't this the ,lowest daily volume for the last several years? OR is the record lo?!!!! What is holding shareholders from buying and selling?